A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Vorinostat (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 26 Apr 2018 Status changed from suspended to not yet recruiting.
- 20 Apr 2018 Planned primary completion date changed from 20 Nov 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated